Global Antibody Hit Generation and Screening Market: Analysis and Forecast, 2023-2032

1.1 Global Market Outlook
1.2 Product Definition
1.3 Inclusion and Exclusion Criteria
1.4 Key Findings
1.5 Assumptions and Limitations
1.6 Global Market Scenario
1.6.1 Realistic Scenario
1.6.2 Optimistic Scenario
1.6.3 Pessimistic Scenario
1.7 Industry Outlook
1.8 Key Trends
1.9 Patent Analysis
1.9.1 Awaited Technological Developments
1.9.2 Patent Filing Trend (by Country/Cluster)
1.9.3 Patent Filing Trend (by Year)
1.10 Product Benchmarking
1.11 Impact of COVID-19 on Global Antibody Hit Generation and Screening Market
1.12 Impact on Market Size
1.12.1 Pre-COVID-19 Phase
1.12.2 During-COVID-19 Phase
1.12.3 Post-COVID-19 Phase
1.13 Market Entry Barriers and Opportunities
1.14 Business Dynamics
1.15 Impact Analysis
1.15.1 Business Drivers
1.15.2 Business Restraints
1.15.3 Business Opportunities

2.1 Opportunity Assessment
2.2 Growth Share Matrix
2.2.1 Hit Generation
2.2.2 Phage display
2.2.3 Yeast display
2.2.4 Ribosome display
2.2.5 B-cell hybridoma technology
2.2.6 Computational tools
2.2.7 Screening

3.1 Opportunity Assessment
3.2 Growth Share Matrix
3.2.1 Humanized Antibody
3.2.2 Human Antibody
3.2.3 Chimeric Antibody
3.2.4 Murine Antibody

4.1 Opportunity Assessment
4.2 Growth Share Matrix
4.2.1 Cancer
4.2.2 Autoimmune diseases
4.2.3 Infectious diseases

5.1 North America Antibody Hit Generation and Screening Market
5.2 Key Findings and Opportunity Assessment
5.3 Regulatory Framework
5.4 Market Dynamics
5.4.1 Impact Analysis
5.5 Sizing and Forecast Analysis
5.5.1 North America Antibody Hit Generation and Screening Market (by Technologies)
5.5.2 North America Antibody Hit Generation and Screening Market (by Country)
5.5.2.1.1 U.S.
5.5.2.1.2 Canada
5.6 Europe Antibody Hit Generation and Screening Market
5.7 Key Findings and Opportunity Assessment
5.8 Regulatory Framework
5.9 Market Dynamics
5.9.1 Impact Analysis
5.10 Sizing and Forecast Analysis
5.10.1 Europe Antibody Hit Generation and Screening Market (by Technologies)
5.10.2 Europe Antibody Hit Generation and Screening Market (by Country)
5.10.2.1.1 Germany
5.10.2.1.2 France
5.10.2.1.3 U.K.
5.10.2.1.4 Italy
5.10.2.1.5 Spain
5.10.2.1.6 Rest-of-Europe
5.11 Asia-Pacific Antibody Hit Generation and Screening Market
5.12 Key Findings and Opportunity Assessment
5.13 Regulatory Framework
5.14 Market Dynamics
5.14.1 Impact Analysis
5.15 Sizing and Forecast Analysis
5.15.1 Asia-Pacific Antibody Hit Generation and Screening Market (by Technologies)
5.15.2 Asia-Pacific Antibody Hit Generation and Screening Market (by Country)
5.15.2.1.1 Japan
5.15.2.1.2 China
5.15.2.1.3 Australia
5.15.2.1.4 India
5.15.2.1.5 South Korea
5.15.2.1.6 Rest-of-Asia-Pacific
5.16 Latin America Antibody Hit Generation and Screening Market
5.17 Key Findings and Opportunity Assessment
5.18 Regulatory Framework
5.19 Market Dynamics
5.19.1 Impact Analysis
5.20 Sizing and Forecast Analysis
5.20.1 Latin America Antibody Hit Generation and Screening Market (by Technologies)
5.20.2 Latin America Antibody Hit Generation and Screening Market (by Country)
5.20.2.1.1 Brazil
5.20.2.1.2 Mexico
5.20.2.1.3 Rest-of-Latin America
5.21 Rest-of-the-World Antibody Hit Generation and Screening Market
5.22 Key Findings and Opportunity Assessment
5.23 Regulatory Framework
5.24 Market Dynamics
5.24.1 Impact Analysis
5.25 Sizing and Forecast Analysis
5.25.1 Rest-of-the-World Antibody Hit Generation and Screening Market (by Technologies)

6.1 Competitive Benchmarking and Company Profiles
6.2 Competitive Landscape
6.2.1 Key Strategies and Developments
6.2.1.1.1 Partnerships, Alliances, and Business Expansion
6.2.1.1.2 Funding Activities
6.2.1.1.3 New Offerings
6.2.1.1.4 Mergers and Acquisitions
6.2.1.1.5 Regulatory and Legal Activities
6.3 Company Profiles
6.3.1 F. Hoffmann-La Roche Ltd.
6.3.2 Company Overview
6.3.3 Product Portfolio
6.3.4 Financials
6.3.5 Recent Developments
6.3.6 Analyst Perspective
6.3.7 AbbVie
6.3.8 Pfizer
6.3.9 AstraZeneca
6.3.10 Novartis
6.3.11 Eli Lilly
6.3.12 WuXi AppTec
6.3.13 Charles River Laboratories
6.3.14 Syngenta
6.3.15 BioLegend
6.3.16 Creative Biolabs
6.3.17 Eurofins CDMO
6.3.18 AbCellera
6.3.19 MorphoSys
6.3.20 Evelo Biosciences
6.3.21 Icos Therapeutics
6.3.22 Argenx
6.3.23 Kymab
6.3.24 Alnylam Pharmaceuticals
6.3.25 SAb Biotherapeutics
6.3.26 Other Companies
** Financials are provided for the public companies only